Cleaves the N-terminal signal peptide of prolipoproteins after the conserved lipobox motif, enabling mature lipoprotein integration into membranes .
Functions as part of the lipoprotein-processing pathway, a target for antibiotic development due to its essential role in Gram-negative bacteria .
| Property | Detail |
|---|---|
| EC Number | 3.4.23.36 |
| Uniprot ID | Q9RRU7 |
| Gene Name | lspA (DR_2388 locus in D. radiodurans strain ATCC 13939) |
| Molecular Function | Aspartyl protease; membrane-bound signal peptidase |
LspA’s conserved active site and essentiality make it a high-priority target for novel antibiotics . Resistance mutations are rare due to functional constraints on substrate binding .
Used in studies probing bacterial membrane protein assembly and lipoprotein trafficking mechanisms .
Structural models aid in rational drug design against multidrug-resistant pathogens .
KEGG: dra:DR_2388
STRING: 243230.DR_2388
Lipoprotein signal peptidase (LspA) is an aspartyl protease that plays a crucial role in the lipoprotein processing pathway of bacteria. It specifically cleaves the transmembrane helix signal peptide of lipoproteins after they have been lipidated. LspA is essential in Gram-negative bacteria and important for virulence in Gram-positive bacteria, making it an excellent target for antibiotic development with potentially low resistance development . In D. radiodurans, as in other bacteria, LspA likely contributes to membrane integrity and protein localization, which may be particularly important given D. radiodurans' exceptional resistance to environmental stressors.
LspA is a membrane-embedded enzyme with several key structural features that enable its function:
A catalytic dyad composed of conserved aspartate residues
A periplasmic helix (PH) that undergoes conformational dynamics
A β-cradle structure that helps position the substrate
The enzyme demonstrates significant conformational flexibility, particularly in the periplasmic helix, which fluctuates on the nanosecond timescale. In the apo (unbound) state, the dominant conformation is closed, occluding the charged active site from the lipid bilayer. This flexibility explains how LspA can accommodate and process a variety of substrate lipoproteins .
Based on protocols used for other bacterial LspA proteins, recombinant D. radiodurans LspA is typically expressed using:
E. coli expression systems with pET vector series (e.g., pET28b)
N-terminal tags such as 6xHis for purification
Thrombin cleavage sequences for tag removal
For example, P. aeruginosa LspA has been successfully expressed using an N-terminal 6xHis tag in a pET28b vector, which could serve as a model for D. radiodurans LspA expression .
A recommended purification protocol based on successful approaches with other bacterial LspA proteins would include:
Expression in E. coli with an N-terminal 6xHis tag
Cell lysis via sonication or French press in buffer containing detergent
Solubilization of membrane fraction using appropriate detergents (e.g., FC12)
Nickel affinity chromatography for initial purification
Optional tag removal using thrombin
Size exclusion chromatography for final purification
Crucial considerations include maintaining proper detergent concentration throughout purification and avoiding protein aggregation .
For effective EPR studies of D. radiodurans LspA:
CW EPR Protocol:
Use single cysteine mutants labeled with spin labels
Utilize FC12 detergent micelles for protein stabilization
Sample volume of approximately 7 μL in 0.6-mm glass capillaries
Perform measurements at room temperature
Avoid DMSO in sample preparation as it impacts spectra
Pulsed EPR (DEER) Protocol:
Prepare double-labeled LspA in FC12 detergent micelles
Use approximately 300 μM protein concentration with 20% deuterated glycerol
Load 15 μL samples into quartz capillaries
Perform measurements at Q-band and 80 K
Use a four-pulse DEER sequence with 16-step phase cycling
For antibiotic binding studies, use a 20:1 molar ratio of antibiotic to protein
Data processing would use appropriate software like DEERAnalysis2018 with Tikhonov regularization .
The most informative mutagenesis approach would target:
Catalytic dyad residues (conserved aspartates) to confirm enzymatic mechanism
Periplasmic helix residues to study conformational dynamics
β-cradle residues that might interact with substrate
Membrane-interfacing residues that could affect stability
When selecting sites for spin labeling:
Avoid highly conserved residues and those with evolutionary coupling
Select sites on β-strands rather than loops for reduced backbone dynamics
Choose sites that are not at tertiary contacts
For distance measurements between domains, select residue pairs within optimal DEER detection range
Appropriate methods include PIPE Mutagenesis or QuikChange protocols, with sequence confirmation by DNA sequencing .
For effective MD simulations of D. radiodurans LspA:
Use an all-atom approach with explicit membrane and solvent
Run multiple independent trajectories to ensure sampling of conformational space
Simulate both apo and antibiotic-bound states for comparison
Analyze periplasmic helix fluctuations and β-cradle interactions
Compare simulation results with experimental EPR data for validation
A hybrid approach combining MD simulations with experimental restraints from EPR would provide the most reliable structural models. This approach has successfully revealed conformational dynamics in LspA from other bacteria that were not apparent from static crystal structures .
To effectively assess inhibition of D. radiodurans LspA:
Develop an in vitro assay using purified recombinant LspA and synthetic peptide substrates
Assess cleavage products using techniques such as HPLC or mass spectrometry
For antibiotic binding studies, test different ratios of inhibitor to enzyme
Include controls to distinguish between competitive and non-competitive inhibition
Correlate functional inhibition with structural changes using EPR or other biophysical methods
For example, when studying globomycin binding to LspA, specific preparation protocols are needed: resuspending globomycin in DMSO at 10 mg/mL, aliquoting and drying in a lyophilizer, then resuspending with the protein sample to avoid DMSO interference with spectroscopic measurements .